Diethylstilbestrol: Intergenerational Impact
(Limited Text - Ministerial Extracts only)
Read Full debate
The Parliamentary Under-Secretary of State for Health and Social Care (Preet Kaur Gill)
I am grateful for the opportunity to respond to this important debate on the intergenerational impact of diethylstilbestrol on women. I begin by applauding the perseverance of my hon. Friend the Member for Bournemouth West (Jessica Toale) and the courage of those affected by the impact of DES, including the campaigners, many of them women, and their families, who have worked for many years to ensure that their experiences are heard and understood. I was honoured to meet some of them earlier today, and I thank them for being here in the Gallery tonight—mothers and daughters, on behalf of their children and grandchildren.
On 5 November 2025, my right hon. Friend the Member for Ilford North (Wes Streeting), the then Secretary of State for Health and Social Care, issued a formal apology on behalf of the Government to all those who have been affected by DES. I wish to reiterate that apology today. At this stage, the Government’s focus is on carefully considering the available evidence and determining the most appropriate next steps, rather than simply establishing a public inquiry. Our current work includes ensuring that appropriate clinical pathways, professional awareness and sources of support are in place for those who may have been affected by DES exposure.
We have taken action to raise awareness of DES among health professionals. On 12 December 2025, Professor Peter Johnson, the national clinical director for cancer, sent a letter to all cancer alliance leaders highlighting the effects of DES and asking them to cascade guidance through their clinical networks to help to reach appropriate health professionals, including GPs. We have also taken steps to improve our knowledge of the impacts of DES. The Department has formally commissioned the University of Exeter, through the National Institute for Health and Care Research, to undertake a systematic evidence review of those impacts, because, as my hon. Friend pointed out, the current research, while useful, does not yet paint a coherent picture. For instance, existing systematic reviews of the physical impacts across first, second and third generations are relatively dated, and have reached differing conclusions. There are also primary research studies that have not yet been incorporated in those reviews, and existing reviews have not fully considered psychosocial impacts. The newly commissioned review is intended to address those gaps.
My hon. Friend asked about screening. The research ensures that any future policy on local treatment pathways, clinical guidance and potential screening arrangements is informed by the latest available evidence. It will also be important in guiding decisions on whether a lifelong screening protocol should be developed for people affected by DES. The women affected by it should, of course, be involved in this work, which is why we ensured that the university will engage with members of DES Justice UK so that it can learn from women—and some men—with lived experience of the effects.
I recognise the importance of trying to understand the scale of DES exposure and the number of people who may have been affected. The Medicines and Healthcare products Regulatory Agency has taken a number of steps to establish what regulatory action was taken by its predecessor in relation to the risk associated with DES. They include searches of agency archives, both digital and hard-copy, for documentation relating to regulatory activity associated with the use of DES; visits to the National Archives to attempt to locate records from the 1970s, including discussions of DES by the Committee on Safety of Medicines, a predecessor of the Commission on Human Medicines; and locating previous editions of the “British National Formulary” and Association of the British Pharmaceutical Industry datasheets that may detail information on the use of DES. The MHRA also contacted the General Medical Council to establish whether any direct communications on DES had been sent by the GMC to healthcare professionals directly, but the GMC could find no records of communications. Finally, there have been searches of the Yellow Card database for any reports of the use of DES, although given the time that has passed, I am sure that the House will appreciate the significant challenges in relation to locating and retrieving records between the 1940s and the 1970s. In addition, my officials are working to explore what can be done through NHS digital processes in relation to missing or destroyed medical records.
Let me again thank Members for raising this important issue, and pay tribute to all those affected by DES who have continued to campaign for recognition, support and answers.
Lisa Smart (Hazel Grove) (LD)
I am here because my constituent Helen, from Romiley, came to see me at my advice surgery on Saturday. I was waiting to raise this point until the Minister was close to ending her speech, because I want to understand what is being done and what more the Government can do to give information to people who think they may be DES daughters. Helen’s mum certainly took something during her pregnancy, but it is difficult to interpret the GP’s handwriting on the records that Helen has received. What can the Minister tell Helen and people like her who think their health conditions suggest that they are DES daughters, but who do not yet have the evidence to show that they are?
Preet Kaur Gill
I thank the hon. Member for her question, and pay tribute to Helen. My hon. Friend mentioned this important issue. While there may be 600 women out there, there are many, many more who just do not know—and, I am sure, grandchildren too. Not only should information be widely available on NHS websites, but women should be able to go to their GPs, and their GPs should be able to direct them to a screening service, while also taking seriously the issues that they raise. More needs to be more done in this regard, and I look forward to working with campaigners and with my hon. Friend to establish what more we can do when we identify gaps.
I pay tribute to the women I met earlier today, who are sitting in the Gallery. Hearing directly from them their powerful testimonies puts a lot of this into context for me. It is not just about reading people’s stories; it is about the lived experience of what that trauma has been like for many women, their grandchildren and so forth. I pay tribute to Clare Fletcher; Marion and Juliette; Heather and her two daughters; Liam, Charly, Anne-Marie and her daughter; and Julia. My apologies if I have missed someone’s name. Thank you so much for sharing your exposure to DES and the fact that the healthcare system did not adequately address the recognised and multigenerational adverse effects of the drug.
We have to continue to listen carefully to those affected, learn from their experiences and take every appropriate step to safeguard people, now and in the future. As someone said, this is not simply a historical medical issue; it is about women whose voices were dismissed, whose experiences were doubted and whose families continue to live with the consequences. It is just a reminder that when women say that something is wrong, we must listen. We cannot change the past, but we can ensure that their voices shape how we respond.
Question put and agreed to.